Johnson & Johnson's Icotyde Shows Strong Potential as a Cash Cow
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 16 2026
0mins
Source: CNBC
- New Drug Launch: Johnson & Johnson's newly launched oral medication Icotyde received FDA approval in mid-March for moderate to severe plaque psoriasis, becoming the first oral treatment targeting the IL-23 receptor, and is expected to become a new cash cow for the company.
- Sales Expectations: Icotyde is projected to reach $10.5 billion in sales by 2032, significantly exceeding Wall Street's consensus of $7.4 billion, indicating strong market potential, especially after securing approvals for conditions like Crohn's disease and ulcerative colitis.
- Market Competition: Despite the convenience of Icotyde, analysts express skepticism about its ability to surpass existing biologics like Tremfya and AbbVie's Skyrizi, suggesting that patients may prefer quarterly injections over daily pills.
- Strategic Positioning: J&J's CEO stated that Icotyde, alongside Tremfya, forms a crucial part of the company's immunology portfolio aimed at replacing declining sales from Stelara, which peaked at nearly $11 billion in 2023 but is expected to see significant declines in the future.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy JNJ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on JNJ
Wall Street analysts forecast JNJ stock price to fall
20 Analyst Rating
13 Buy
7 Hold
0 Sell
Moderate Buy
Current: 234.340
Low
190.00
Averages
218.50
High
240.00
Current: 234.340
Low
190.00
Averages
218.50
High
240.00
About JNJ
Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Johnson & Johnson Acquires Gemtrack Technology Rights
- Technology Acquisition: Johnson & Johnson's DePuy Synthes has acquired rights to develop, manufacture, and commercialize Gemtrack technology from MinMax Medical, aiming to advance radiofrequency tracking in joint reconstruction surgeries and potentially set a new industry standard.
- Market Potential: The Gemtrack RF tracking technology is expected to eliminate the need for infrared cameras, reduce reliance on invasive anchors, and enable continuous, highly accurate real-time tracking, thereby enhancing surgical safety and efficiency.
- Application Scope: This technology can be applied to shoulder, hip, and knee procedures for navigation and robotic assistance, strengthening DePuy Synthes's competitive position in orthopedic surgery and addressing market demands for high-precision operations.
- Strategic Implications: By integrating Gemtrack technology, DePuy Synthes not only enhances the technological sophistication of its product line but also positions itself to lead in the future medical device market, driving long-term growth for the company.
See More
Declining Appeal of U.S. Treasuries Amid Rising Corporate Debt Interest
- Rising Treasury Yields: The yield on the two-year Treasury note has increased by 60 basis points this year, surpassing 4.00%, primarily due to the energy price surge from the Iran war, which is expected to compel the Federal Reserve to raise interest rates, thereby heightening investor concerns about Treasuries.
- Strong Corporate Debt Performance: Many blue-chip companies have outperformed Treasuries, with Apple's two-year bond yield narrowing to just 3 basis points above the Treasury yield, marking a record low spread and indicating a growing appeal of corporate debt over government bonds.
- Credit Rating Discrepancies: Microsoft and Johnson & Johnson are the only U.S. companies to hold AAA ratings from the three major agencies, while the U.S. government no longer has a AAA rating, reflecting that the risk of lending to corporations is now comparable to that of Treasuries, prompting investors to reassess risk-reward dynamics.
- Long-Term Investment Concerns: While corporate debt is viewed as lower risk, investors must consider long-term repayment capabilities, especially amid escalating global AI competition, which introduces uncertainties about companies' futures and their ability to meet debt obligations.
See More
Comparing Dividend Kings: Procter & Gamble vs. Johnson & Johnson
- Dividend King Criteria: To be classified as a Dividend King, a company must increase its dividend for at least 50 consecutive years, a standard that highlights the ability of firms like Procter & Gamble and Johnson & Johnson to maintain stability through economic fluctuations, showcasing their robust business models and brand loyalty.
- Procter & Gamble's Market Position: With a market cap of $336 billion and a dividend yield of 2.95%, Procter & Gamble is considered a solid investment choice despite its valuation metrics being below five-year averages, particularly as consumer demand for essentials remains consistent amid economic uncertainty.
- Johnson & Johnson's Competitive Edge: Johnson & Johnson boasts a market cap of $564 billion and a 5.7% annual dividend growth rate, benefiting from patent protections in its pharmaceutical and medical device sectors, which ensures stable revenue streams even during economic downturns, reinforcing its leadership in the healthcare industry.
- Legal Risks and Market Opportunities: While Johnson & Johnson faces legal challenges related to talcum powder, its diversified business model and ongoing investment in research and development position it well to navigate market uncertainties, further solidifying its status as a Dividend King.
See More
Johnson & Johnson: A Strong Dividend King Investment
- Stable Dividend Growth: Johnson & Johnson has increased its dividend annually for 50 consecutive years, with an average growth rate of 5.7%, demonstrating a robust business model and adaptability in the face of economic uncertainty, which attracts long-term investor interest.
- Strong Demand for Medical Products: J&J's medical and pharmaceutical products benefit from patent protections, ensuring its market position in healthcare, as consumers have little choice when it comes to necessary medical services, thereby enhancing revenue stability and risk resilience.
- Relative Valuation Analysis: Although J&J's valuation metrics are above its five-year averages, its dividend yield exceeds 2.2%, double that of the broader market, indicating that investors are willing to pay a premium for its diversified and resilient business in the current market environment.
- Legal Risk Consideration: J&J faces legal challenges related to talcum powder, which may concern some investors; however, the management's ability to address these issues could further validate the company's fundamental strength and capacity to navigate adversity.
See More
Wall Street Trading Week Outlook and Focus
- Salesforce Earnings Outlook: Salesforce is set to report earnings on Wednesday, with market concerns about its AI business still prevalent; analysts expect revenue of $11.05 billion and EPS of $3.12, and strong revenue growth could alleviate worries about slowing growth in its legacy business.
- Costco Membership Renewal Challenges: Costco will report earnings on Thursday, with expected revenue of $69.73 billion and EPS of $4.93; while high oil prices may pressure profit margins, its membership model and bulk selling strategy are likely to attract consumers, especially during periods of rising gas prices.
- Economic Data Focus: The personal consumption expenditures (PCE) price index will be released on Thursday, with a year-over-year increase expected at 3.8% and a core increase of 3.3%, which will influence the Federal Reserve's rate hike decisions, leaving the market uncertain about future rate changes.
- Investor Conference Season: This week marks the start of investor conference season, with Boeing, Johnson & Johnson, and others attending the Bernstein Strategic Decisions Conference, where analyst questions may reveal insights into market perceptions of company futures, making it a key event to watch.
See More
Direct Indexing Strategy Boosts Retirement Income Potential
- Income Potential: A 65-year-old couple can generate approximately $19,000 annually from a $700,000 investment portfolio using a direct indexing strategy, which combines dividends and tax-loss harvesting, highlighting the strategy's effectiveness and appeal.
- Dividend Composition: Supported by major dividend payers like Johnson & Johnson (JNJ), Procter & Gamble (PG), Coca-Cola (KO), Exxon Mobil (XOM), and Microsoft (MSFT), the dividend yield is around 2.0%, providing investors with a stable cash flow.
- Tax-Loss Harvesting Advantage: The direct indexing strategy allows for selling individual stocks that decline, utilizing harvested losses to offset capital gains, with expected annual increases in after-tax returns of 0.5% to 1.5%, further enhancing overall portfolio returns.
- Portfolio Flexibility: This strategy enables investors to manage their portfolios flexibly while maintaining market exposure, optimizing returns through market volatility, thereby achieving higher capital appreciation and income growth over the long term.
See More
Johnson & Johnson Acquires Gemtrack Technology Rights
- Technology Acquisition: Johnson & Johnson's DePuy Synthes has acquired rights to develop, manufacture, and commercialize Gemtrack technology from MinMax Medical, aiming to advance radiofrequency tracking in joint reconstruction surgeries and potentially set a new industry standard.
- Market Potential: The Gemtrack RF tracking technology is expected to eliminate the need for infrared cameras, reduce reliance on invasive anchors, and enable continuous, highly accurate real-time tracking, thereby enhancing surgical safety and efficiency.
- Application Scope: This technology can be applied to shoulder, hip, and knee procedures for navigation and robotic assistance, strengthening DePuy Synthes's competitive position in orthopedic surgery and addressing market demands for high-precision operations.
- Strategic Implications: By integrating Gemtrack technology, DePuy Synthes not only enhances the technological sophistication of its product line but also positions itself to lead in the future medical device market, driving long-term growth for the company.
See More
Declining Appeal of U.S. Treasuries Amid Rising Corporate Debt Interest
- Rising Treasury Yields: The yield on the two-year Treasury note has increased by 60 basis points this year, surpassing 4.00%, primarily due to the energy price surge from the Iran war, which is expected to compel the Federal Reserve to raise interest rates, thereby heightening investor concerns about Treasuries.
- Strong Corporate Debt Performance: Many blue-chip companies have outperformed Treasuries, with Apple's two-year bond yield narrowing to just 3 basis points above the Treasury yield, marking a record low spread and indicating a growing appeal of corporate debt over government bonds.
- Credit Rating Discrepancies: Microsoft and Johnson & Johnson are the only U.S. companies to hold AAA ratings from the three major agencies, while the U.S. government no longer has a AAA rating, reflecting that the risk of lending to corporations is now comparable to that of Treasuries, prompting investors to reassess risk-reward dynamics.
- Long-Term Investment Concerns: While corporate debt is viewed as lower risk, investors must consider long-term repayment capabilities, especially amid escalating global AI competition, which introduces uncertainties about companies' futures and their ability to meet debt obligations.
See More
Comparing Dividend Kings: Procter & Gamble vs. Johnson & Johnson
- Dividend King Criteria: To be classified as a Dividend King, a company must increase its dividend for at least 50 consecutive years, a standard that highlights the ability of firms like Procter & Gamble and Johnson & Johnson to maintain stability through economic fluctuations, showcasing their robust business models and brand loyalty.
- Procter & Gamble's Market Position: With a market cap of $336 billion and a dividend yield of 2.95%, Procter & Gamble is considered a solid investment choice despite its valuation metrics being below five-year averages, particularly as consumer demand for essentials remains consistent amid economic uncertainty.
- Johnson & Johnson's Competitive Edge: Johnson & Johnson boasts a market cap of $564 billion and a 5.7% annual dividend growth rate, benefiting from patent protections in its pharmaceutical and medical device sectors, which ensures stable revenue streams even during economic downturns, reinforcing its leadership in the healthcare industry.
- Legal Risks and Market Opportunities: While Johnson & Johnson faces legal challenges related to talcum powder, its diversified business model and ongoing investment in research and development position it well to navigate market uncertainties, further solidifying its status as a Dividend King.
See More
Johnson & Johnson: A Strong Dividend King Investment
- Stable Dividend Growth: Johnson & Johnson has increased its dividend annually for 50 consecutive years, with an average growth rate of 5.7%, demonstrating a robust business model and adaptability in the face of economic uncertainty, which attracts long-term investor interest.
- Strong Demand for Medical Products: J&J's medical and pharmaceutical products benefit from patent protections, ensuring its market position in healthcare, as consumers have little choice when it comes to necessary medical services, thereby enhancing revenue stability and risk resilience.
- Relative Valuation Analysis: Although J&J's valuation metrics are above its five-year averages, its dividend yield exceeds 2.2%, double that of the broader market, indicating that investors are willing to pay a premium for its diversified and resilient business in the current market environment.
- Legal Risk Consideration: J&J faces legal challenges related to talcum powder, which may concern some investors; however, the management's ability to address these issues could further validate the company's fundamental strength and capacity to navigate adversity.
See More
Wall Street Trading Week Outlook and Focus
- Salesforce Earnings Outlook: Salesforce is set to report earnings on Wednesday, with market concerns about its AI business still prevalent; analysts expect revenue of $11.05 billion and EPS of $3.12, and strong revenue growth could alleviate worries about slowing growth in its legacy business.
- Costco Membership Renewal Challenges: Costco will report earnings on Thursday, with expected revenue of $69.73 billion and EPS of $4.93; while high oil prices may pressure profit margins, its membership model and bulk selling strategy are likely to attract consumers, especially during periods of rising gas prices.
- Economic Data Focus: The personal consumption expenditures (PCE) price index will be released on Thursday, with a year-over-year increase expected at 3.8% and a core increase of 3.3%, which will influence the Federal Reserve's rate hike decisions, leaving the market uncertain about future rate changes.
- Investor Conference Season: This week marks the start of investor conference season, with Boeing, Johnson & Johnson, and others attending the Bernstein Strategic Decisions Conference, where analyst questions may reveal insights into market perceptions of company futures, making it a key event to watch.
See More
Direct Indexing Strategy Boosts Retirement Income Potential
- Income Potential: A 65-year-old couple can generate approximately $19,000 annually from a $700,000 investment portfolio using a direct indexing strategy, which combines dividends and tax-loss harvesting, highlighting the strategy's effectiveness and appeal.
- Dividend Composition: Supported by major dividend payers like Johnson & Johnson (JNJ), Procter & Gamble (PG), Coca-Cola (KO), Exxon Mobil (XOM), and Microsoft (MSFT), the dividend yield is around 2.0%, providing investors with a stable cash flow.
- Tax-Loss Harvesting Advantage: The direct indexing strategy allows for selling individual stocks that decline, utilizing harvested losses to offset capital gains, with expected annual increases in after-tax returns of 0.5% to 1.5%, further enhancing overall portfolio returns.
- Portfolio Flexibility: This strategy enables investors to manage their portfolios flexibly while maintaining market exposure, optimizing returns through market volatility, thereby achieving higher capital appreciation and income growth over the long term.
See More
